Ortho's (OCDX) VITROS SARS-CoV-2 Antigen Test for High-Volume Testing Receives FDA Emergency Use Authorization for New Performance, Sensitivity Data

March 23, 2021 8:06 AM EDT
Get Alerts OCDX Hot Sheet
Price: $18.64 -3.92%

Overall Analyst Rating:
    BUY (= Flat)

Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it received authorization from the U.S. Food and Drug Administration to update key claims for the VITROS® SARS-CoV-2 Antigen Test, the first high-volume SARS-CoV-2 antigen assay to receive Emergency Use Authorization (EUA) in the United States.

"Communities and laboratories across the United States continue to seek fast, reliable, simplified diagnostic solutions to help them tackle the volume of COVID-19 tests needed to aid safe reopening measures," said Chockalingam Palaniappan, PhD, chief innovation officer, Ortho Clinical Diagnostics. "Ortho Clinical Diagnostics continues to innovate to provide them with solutions—including our antigen test with new performance and sensitivity data, that enable fast, high-volume testing with accurate results."

New FDA-Emergency Use Authorized Only Claims Include:

  • Improved Sensitivity DataThe VITROS® SARS-CoV-2 Antigen Test demonstrates 94.8% sensitivity for samples with a PCR cycle threshold (CT— an assessment of viral load), of less than 30.1 Studies 2,3 have shown that samples with PCR CT values at 30 - 33 or greater carry little to no live virus, suggesting these patients may no longer be infectious. This further solidifies the test's clinical utility in identifying individuals who are in the acute stage of COVID-19 infection when the risk for viral transmission is the highest.
  • Updated Specimen Collection MethodsWhen utilizing Ortho's antigen test, personnel at hospitals, reference labs, and other healthcare settings will now be able to use a nasal sample which is more convenient than the nasopharyngeal swab specimen collection method. Further, the authorization allows for easier and faster sample collection.4
  • Additional Viral Transport Media (VTM)Testing leaders will now be able to utilize three additional viral transport media (VTM) options. Designed to preserve the integrity of collected samples during transportation to laboratories, new VTM options authorized for use with the VITROS® SARS-CoV-2 Antigen Test include Saline, which is readily available and cost effective, or Phosphate Buffered Saline (PBS), Bartels FlexTrans™ transport media [Trinity Biotech], and the World Health Organization's formulation of VTM, in addition to the CDC's formulation of VTM, COPAN Universal Transport Media (UTM)®, and Hardy R99 VTM—expanding options and testing capacity for customers who use Ortho's antigen assay.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Hot FDA News, Management Comments

Related Entities

Twitter, FDA